# Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/dabrafenib-plus-trametinib-in-patients-with-previously-untreated-brafv600e/

## Facts

| Field | Value |
| --- | --- |
| Author Names | David Planchard,Egbert F. Smit,Harry J.M. Groen,Julien Mazières,Benjamin Besse,Åslaug Helland,Vanessa Giannone,Anthony M. D’Amelio,Pingkuan Zhang,Bijoyesh Mookerjee,Bruce E. Johnson |
| Citations | 1,372 |
| DOI | 10.1016/s1470-2045(17)30679-4 |
| Fields | Biochemistry, Genetics and Molecular Biology,Chemistry,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | http://www.thelancet.com/article/S1470204517306794/pdf |
| OpenAlex ID | https://openalex.org/W2409383155 |
| PMID | 28919011 |
| Type | article |
| Year | 2017 |

## Paper authors

- [David Planchard](https://scholariq.org/researchers/david-planchard/)
- [Benjamin Besse](https://scholariq.org/researchers/benjamin-besse/)
- [Julien Mazières](https://scholariq.org/researchers/julien-mazieres/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

## Paper topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Synthesis and biological activity](https://scholariq.org/topics/synthesis-and-biological-activity/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.